Health Advocates Issue One-Year Report Card on Addyi, the Female Libido Drug

FOR IMMEDIATE RELEASE Contact: Shaniqua Seth at or 202.682-2640, ext. 225 WASHINGTON, DC – August 18th marks the one-year anniversary of the Food and Drug Administration’s (FDA) approval of flibanserin (brand name: Addyi), the so-called “female Viagra” pill. In light of recent developments, the National Women’s Health Network (NWHN) has issued a one-year report … Continued

Addyi Report: One Year Later!

One year ago today, the FDA buckled to pressure from a savvy astroturf campaign and approved the female libido drug flibanserin (brand name: Addyi). In response, we launched the “Pass on the Pink Pill – Or Pass Out” campaign to warn women of the marginal benefits and serious side effects of the “pink pill”—complications like … Continued

Addyi 1 Year Later: What’s the Score?

Click image to download PDF of the report card Report Card References 1 – Addyi’s FDA Warning Addyi’s life-threatening side effects were so grave that they warranted the strictest possible warning by the FDA—a “black box warning.” Those side effects include severe, sudden drops in blood pressure that can lead to loss of consciousness for … Continued

New Campaign Warns Women of Harm from Drug FDA Approved in August

FOR IMMEDIATE RELEASE To schedule an interview with Cindy Pearson contact: Sarah Courtney at or 917-913-1994   Feminist Health Advocates Cite Unsafe Sex Drug for Women in Call for Next FDA Commissioner to Resist Political Pressure WASHINGTON, D.C. – As Dr. Robert Califf testifies before the Senate on his nomination for commissioner of the Food and Drug … Continued

Warning of marginal benefits and serious side effects as drug sales begin

FOR IMMEDIATE RELEASE To schedule an interview with Cindy Pearson and Susan Wood: Sarah Courtney at or 917-913-1994   “PASS ON THE PINK PILL – OR PASS OUT!” Health Advocates Issue Emergency Alert on Addyi:  The New Sex Drug for Women WASHINGTON, DC – The consumer advocacy group National Women’s Health Network (NWHN) today issued its first ever … Continued